Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024 , DOI: 10.1200/jco.23.02018
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Camille Abboud, Nebu Koshy, Patrick Stiff, Benjamin Tomlinson, Sunil Abhyankar, James Foran, Parameswaran Hari, George Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Orozco, Katarzyna Jamieson, Margarida Silverman, Koen Van Besien, Michael Schuster, Arjun Datt Law, Karilyn Larkin, Neeta Pandit-Taskar, Scott D. Rowley, Pashna Munshi, Rachel Cook, Moshe Y. Levy, Hillard M. Lazarus, Brenda M. Sandmaier, John M. Pagel, Vijay Reddy, James MacDougall, Kathleen McNamara, Jennifer Spross, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, Avinash Desai, Sergio Giralt

Journal of Clinical Oncology, Ahead of Print.

中文翻译：